PMID- 34692850
OWN - NLM
STAT- MEDLINE
DCOM- 20220207
LR  - 20220207
IS  - 2314-7156 (Electronic)
IS  - 2314-8861 (Print)
IS  - 2314-7156 (Linking)
VI  - 2021
DP  - 2021
TI  - Immunological Changes in Peripheral Blood of Ankylosing Spondylitis Patients 
      during Anti-TNF-alpha Therapy and Their Correlations with Treatment Outcomes.
PG  - 1017938
LID - 10.1155/2021/1017938 [doi]
LID - 1017938
AB  - Tumor necrosis factor-alpha (TNF-alpha) inhibitors are the main types of biological 
      conventional synthetic disease-modifying antirheumatic drugs and have efficacy in 
      treating ankylosing spondylitis (AS) which is not sensitive for nonsteroidal 
      anti-inflammatory drug. However, the impact of TNF-alpha inhibitors on immune cells 
      in patients with AS is still clearly undefined, and the impact of immune cells on 
      treatment response is also largely elusive. This study is aimed at evaluating the 
      longitudinal changes of circulating immune cells after anti-TNF-alpha therapy and 
      their associations with treatment response in AS patients. Thirty-five AS 
      patients receiving the treatment of anti-TNF-alpha therapy were included into this 
      prospective observational study. The frequencies of immune cells including Th1, 
      Th2, Th17, regulatory T cell (Treg), T follicular helper cell (Tfh), and 
      regulatory B cell (Breg) in the peripheral blood were measured by flow cytometry 
      at baseline and 4 time points after therapy. The difference in the circulating 
      immune cells between responders and nonresponders was compared. This study 
      suggested that anti-TNF-alpha therapy could significantly reduce circulating 
      proinflammatory immune cells such as Th17 and Tfh, but significantly increased 
      the percentages of circulating Treg and Breg. Moreover, circulating Breg may be a 
      promising predictor of response to anti-TNF-alpha therapy in AS patients.
CI  - Copyright (c) 2021 Rongjuan Chen et al.
FAU - Chen, Rongjuan
AU  - Chen R
AUID- ORCID: 0000-0001-7365-584X
AD  - Xiamen Key Laboratory of Rheumatology and Clinical Immunology, The First 
      Affiliated Hospital of Xiamen University, Xiamen 361003, China.
FAU - Qian, Hongyan
AU  - Qian H
AD  - Xiamen Key Laboratory of Rheumatology and Clinical Immunology, The First 
      Affiliated Hospital of Xiamen University, Xiamen 361003, China.
FAU - Yuan, Xiaoqing
AU  - Yuan X
AD  - Xiamen Key Laboratory of Rheumatology and Clinical Immunology, The First 
      Affiliated Hospital of Xiamen University, Xiamen 361003, China.
FAU - Chen, Shiju
AU  - Chen S
AD  - Xiamen Key Laboratory of Rheumatology and Clinical Immunology, The First 
      Affiliated Hospital of Xiamen University, Xiamen 361003, China.
FAU - Liu, Yuan
AU  - Liu Y
AD  - Xiamen Key Laboratory of Rheumatology and Clinical Immunology, The First 
      Affiliated Hospital of Xiamen University, Xiamen 361003, China.
FAU - Wang, Bin
AU  - Wang B
AUID- ORCID: 0000-0002-6985-8289
AD  - Xiamen Key Laboratory of Rheumatology and Clinical Immunology, The First 
      Affiliated Hospital of Xiamen University, Xiamen 361003, China.
FAU - Shi, Guixiu
AU  - Shi G
AUID- ORCID: 0000-0003-4044-3394
AD  - Xiamen Key Laboratory of Rheumatology and Clinical Immunology, The First 
      Affiliated Hospital of Xiamen University, Xiamen 361003, China.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20211015
PL  - Egypt
TA  - J Immunol Res
JT  - Journal of immunology research
JID - 101627166
RN  - 0 (Tumor Necrosis Factor Inhibitors)
SB  - IM
MH  - Adult
MH  - B-Lymphocytes, Regulatory/drug effects/*immunology
MH  - CD4-Positive T-Lymphocytes/drug effects/*immunology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Longitudinal Studies
MH  - Lymphocyte Count
MH  - Male
MH  - Prospective Studies
MH  - Severity of Illness Index
MH  - Spondylitis, Ankylosing/blood/diagnosis/*drug therapy/immunology
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor Inhibitors/pharmacology/*therapeutic use
PMC - PMC8536454
COIS- All authors declare that they have no conflict of interest in this paper.
EDAT- 2021/10/26 06:00
MHDA- 2022/02/08 06:00
PMCR- 2021/10/15
CRDT- 2021/10/25 06:40
PHST- 2021/05/11 00:00 [received]
PHST- 2021/09/11 00:00 [accepted]
PHST- 2021/10/25 06:40 [entrez]
PHST- 2021/10/26 06:00 [pubmed]
PHST- 2022/02/08 06:00 [medline]
PHST- 2021/10/15 00:00 [pmc-release]
AID - 10.1155/2021/1017938 [doi]
PST - epublish
SO  - J Immunol Res. 2021 Oct 15;2021:1017938. doi: 10.1155/2021/1017938. eCollection 
      2021.